Avalyn Pharma Inc. Common Stock's latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 5 Aug 2026Company is spending more money on office space, which reduces cash available for drug development.
Finishing enrollment means the drug trial is progressing on schedule toward results that could prove the medicine works.
Quarterly earnings show whether the company is spending money wisely as it develops its lung disease drug.
Quarterly earnings show whether the company is spending money wisely as it develops its lung disease drug.
Updated corporate rules take effect after the company goes public, affecting how it operates and makes decisions.
Company raises $279 million by selling stock to the public, giving it money to fund drug development.
Company begins process to sell stock publicly, which will raise cash to pay for drug trials and operations.
Stocky reads Avalyn Pharma Inc. Common Stock's official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Avalyn Pharma Inc. Common Stock's most recent tracked filing was a 8-K on 1 Jul 2026: Expands Boston office space, adds $924,000 to lease costs.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 5 Aug 2026.